Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Heather Clinical Research Ltd Co

Neither a doctor nor a teaching hospital

Research payments

$1,144,675

377 payments

Through program year 2025, Heather Clinical Research Ltd Co is reported as receiving $1,144,675 in research payments, across 377 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $13,200 4
2024 Research $46,104 2
2023 Research $43,041 33
2022 Research $81,938 115
2021 Research $404,719 89
2020 Research $224,729 69
2019 Research $330,944 65

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $451,719 52 payments
  2. Noven Pharmaceuticals, Inc. $183,538 4 payments
  3. AstraZeneca Pharmaceuticals LP $91,835 4 payments
  4. Esperion Therapeutics, Inc. $85,933 208 payments
  5. Kowa Research Institute, Inc. $78,998 41 payments
  6. Eli Lilly and Company $60,000 2 payments
  7. Evofem Biosciences, Inc. $55,332 10 payments
  8. Sunovion Pharmaceuticals Inc. $52,641 35 payments
  9. Amgen Inc. $38,470 5 payments
  10. Gilead Sciences, Inc. $33,008 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. M16-100 $319,648 25 payments
  2. A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee $183,538 4 payments
  3. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $94,290 11 payments
  4. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $85,933 208 payments
  5. A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $60,000 2 payments
  6. A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures $52,641 35 payments
  7. K-877-302 $47,266 21 payments
  8. A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) $45,731 2 payments
  9. Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection $40,185 6 payments
  10. FOURIER OLE (Ph 4) $37,564 3 payments
What the money was spent on Research payments · program years 2019–2025
  1. Professional salary support $40,185 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record